- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Ramucirumab – July 2019
Ramucirumab: 100 mg in 10 mL vial, 500 mg in 50 mL vial; Cyramza®
Last updated
15 November 2019